IPO Listed — 01 Sep 2026

Listing Price: ₹988 (+0% vs ₹988)

View GMP History →

IPO Details GMP Review

More sections

Other pages for this IPO

Subscription Allotment

Symbiotec Pharmalab IPO Review

Q: What was the actual listing price of Symbiotec Pharmalab IPO?

Symbiotec Pharmalab IPO listed on September 1, 2026 at ₹988, against the issue price of ₹988 — a gain of +0% (₹0 per share).

Q: What is the price band and lot size of Symbiotec Pharmalab IPO?

Symbiotec Pharmalab IPO is priced at ₹938-988 per share. The minimum lot size is 15 shares, making the minimum investment approximately ₹14,820 at the upper end of the price band. Subscription ran from 24 Aug 2026 to 27 Aug 2026.

Symbiotec Pharmalab IPO has been reviewed by 11 analysts, and the overall consensus is Strong Apply — carrying a score of 94. Out of the 11 analysts who have covered this IPO, 9 recommend subscribing while 2 advise caution or avoidance — reflecting a mixed view from the analyst community.

The issue is priced in the band of ₹938-988 per share , with a minimum application size of 15 shares (minimum investment of approximately ₹14,820 at the upper band) . Subscription ran from 24 Aug 2026 to 27 Aug 2026. As of now, the grey market premium (GMP) for Symbiotec Pharmalab IPO is quoting at ₹185 (18.72%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.

General Review

Symbiotec, set up in 2002 at Indore, makes over 60 corticosteroid and steroidal hormone APIs and is the only company in the world present across the top ten products by volume, holding 38.2 percent global share in corticosteroids. FY26 EBITDA margin was a healthy 27.4 percent. Nine of the eleven analysts covering it said subscribe, giving this issue the widest coverage and a clearly positive consensus.

Listing Gains

At ₹988 the issue comes at 53 to 58 times FY26 earnings and EV/EBITDA near 27.6 times, on a post-issue market cap of about ₹6,244 crore. Peers trade between 58 and 163 times, so it is cheaper than peers but still expensive on its own numbers. Most analysts call it reasonably valued, a few flag it as rich. Expect a moderate listing gain.

Short Term Strategy

Short-term upside looks limited. Revenue grew at just 10.16 percent CAGR and profit at 4.81 percent over FY24 to FY26, and FY25 profit was actually below FY24. Only ₹150 crore of the ₹1,757 crore raised comes to the company, so the issue adds nothing to earnings, while finance cost has risen from ₹7.24 crore to ₹25.33 crore. Patience is needed.

Long Term Strategy

This is where the real story sits. A record of 43 US DMFs and 23 EDQM CEPs takes years to build and keeps competition out, and backward integration covers key starting materials for over 80 percent of products by revenue. New fermentation, CDMO and complex injectable plants at Ujjain and Mhow are the next growth legs. Several analysts recommended it specifically for a long horizon.

Disclaimer: This review is an AI summary derived from the reviews of all analysts.

Analyst Verdict & Score
Detailed Review
Analyst Reviews
Frequently Asked Questions

Analyst Sentiment

Analytical Score

How it's calculated?

Strong Apply

94 / 100

Recommend Subscribe

Based on 11 analyst reviews

9 / 11

Higher consensus indicates broader analyst agreement.

Analyst Review

Analyst	Verdict	View
Nirmal Bang	Apply
Adroit Financial Services	Apply
Anand Rathi	Apply
BP Equities	Apply
SBI Securities	Apply
Kantilal Chhaganlal Securities	Apply
Angel One	Apply
Marwadi Shares & Finance	May Apply
Ventura Securities	Apply
Capital Market	May Apply
Swastika Investmart	Apply

Latest IPO Reviews

Manika Plastech Strong Apply

Score

Veegaland Developers Apply

Score

Rentomojo Apply

Score

Asset Reconstruction Co.(India) Strong Apply

Score

Frequently Asked Questions

Should I apply for Symbiotec Pharmalab IPO?

Based on analyst coverage tracked on this page, the overall verdict for Symbiotec Pharmalab IPO is Strong Apply. Out of 11 analysts who have reviewed this IPO, 9 recommend subscribing. Always cross-check with the full analyst reviews below and consult a SEBI-registered advisor before making any investment decision.

What does the score of 94 mean for Symbiotec Pharmalab IPO?

The score of 94 is an aggregate of all analyst ratings tracked for Symbiotec Pharmalab IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe. Scroll down to read individual analyst verdicts for more context.

What was the actual listing price of Symbiotec Pharmalab IPO?

Symbiotec Pharmalab IPO listed on September 1, 2026 at ₹988 , against the issue price of ₹988 — a gain of +0% (₹0 per share). View the full GMP history page for day-wise pre-listing trends.

What is the price band and lot size of Symbiotec Pharmalab IPO?

Symbiotec Pharmalab IPO was priced at ₹938-988 per share. The minimum lot size is 15 shares, making the minimum investment approximately ₹14,820 at the upper end of the price band. Subscription ran from 24 Aug 2026 to 27 Aug 2026.

Explore Symbiotec Pharmalab IPO Further

Track every stage of this IPO:

📈

GMP Today

Live grey market premium

📊

Subscription Status

Real-time bidding data

📋

Allotment Status

Check if you got shares

Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.